Dr. Morie Gertz currently holds the title of Professor of Medicine and his primary appointment is as a consultant in the Division of Hematology, Department of Internal Medicine at the Mayo Clinic, Rochester, MN, USA. Dr. Gertz has major research interests in amyloidosis and Multiple Myeloma (MM). In particular, Dr. Gertz studies relapse rates in patients with MM and amyloidosis when treated with novel versus traditional therapies. His areas of focus include primary amyloidosis, stem cell transplantation, amyloidosis and Waldenström’s macroglobulinemia.
Dr. Gertz completed a BA in Arts and Sciences at Northwestern University, before completing his medical studies at the Loyola University & Stritch School of Medicine in Chicago, USA. He then undertook two internships at Saint Joseph's Hospital and at the Rush Presbyterian-St. Luke's Medical Center, in Chicago, before taking up a residency in Internal Medicine at Rush Presbyterian-St. Luke's Medical Center. After this he took up a fellowship at Department of Hematology and Oncology Mayo Graduate School of Medicine, Mayo Clinic College of Medicine, where he has remained for the duration of his career.
Dr. Gertz holds a number of professional affiliations. He is a member of the Committee on Training for the American Society of Hematology, a member of the Hematology Board Exam Committee, American Board of Internal Medicine and was Treasurer of the International Myeloma Society (IMS) from 2011–2014. In recognition of his work, he received the Waldenström Award for medical and scientific achievements in Waldenström's macroglobulinemia in 2014.